drug

Sodium Butyrate

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Nathan Kline Institute for Psychiatric Research
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
NCT03010865Phase 2, Phase 3Withdrawn
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
NCT02654405Phase 2, Phase 3Withdrawn

KOLs & investigators

2
Robert C Smith, M.D., Ph.DKOL score 5
Chunbo Li, Ph.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Nathan Kline Institute for Psychiatric Research
company
trial
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
PHASE2, PHASE3
trial
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
PHASE2, PHASE3
trial
indication
Schizophrenia
indication
Schizophrenic Disorders
indication
Inflammation
indication
Cognitive Impairment
indication
KOL
Robert C Smith, M.D., Ph.D
KOL score 5
person
Chunbo Li, Ph.D.
KOL score —
person